genOway Chosen by Tufts University for Major Framework Contract
News Dec 28, 2009
genOway reports an important framework agreement with the Tufts University (Boston, USA).
Following an international competition, the company has been selected for a framework contract for a two years renewable period.
Under the terms of the agreement, researchers at the Tufts University, whose prestigious areas of study cover oncology, cardiovascular disease and virology (especially AIDS), will benefit from the expertise gained by genOway in transgenic technologies and technological innovations developed by the company, such as inducible systems that secure and accelerate the development of sophisticated genetically modified mouse and rat models.
The financial terms of the agreement were not disclosed.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.